CN114632040A - Composition with relieving effect and preparation and application thereof - Google Patents
Composition with relieving effect and preparation and application thereof Download PDFInfo
- Publication number
- CN114632040A CN114632040A CN202210253643.1A CN202210253643A CN114632040A CN 114632040 A CN114632040 A CN 114632040A CN 202210253643 A CN202210253643 A CN 202210253643A CN 114632040 A CN114632040 A CN 114632040A
- Authority
- CN
- China
- Prior art keywords
- composition
- extract
- application
- amino acid
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 230000000694 effects Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 78
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 18
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 18
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 17
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 17
- 229940001584 sodium metabisulfite Drugs 0.000 claims abstract description 14
- 241000207929 Scutellaria Species 0.000 claims abstract description 12
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 10
- 241000736199 Paeonia Species 0.000 claims abstract description 9
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 241000167550 Centella Species 0.000 claims abstract description 5
- 239000007921 spray Substances 0.000 claims description 19
- 239000002537 cosmetic Substances 0.000 claims description 18
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims description 12
- 229940059958 centella asiatica extract Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 abstract description 13
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 59
- 108010003272 Hyaluronate lyase Proteins 0.000 description 27
- 102000001974 Hyaluronidases Human genes 0.000 description 27
- 229960002773 hyaluronidase Drugs 0.000 description 27
- 239000003814 drug Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 239000000523 sample Substances 0.000 description 15
- 239000002994 raw material Substances 0.000 description 12
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 235000004879 dioscorea Nutrition 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 230000037307 sensitive skin Effects 0.000 description 5
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940084032 paeonia lactiflora root extract Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- -1 tea leaf extract Substances 0.000 description 1
- 229940092665 tea leaf extract Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a composition with a soothing effect, and preparation and application thereof. The composition comprises the following components in percentage by mass: 0.3-1.0% of dipotassium glycyrrhizinate, 0.01-0.5% of peony root extract, 0.05-0.5% of scutellaria root extract, 0.05-0.5% of centella extract, 0.01-0.3% of amino acid, 0.005-0.1% of citric acid, 0.005-0.05% of sodium metabisulfite, 40-60% of polyalcohol and the balance of water. The composition disclosed by the invention is high in safety and good in stability, and can effectively play the roles of anti-allergy and anti-oxidation, so that the effect of relieving the skin is realized.
Description
Technical Field
The invention belongs to the technical field of cosmetics. More particularly, it relates to a composition with soothing effect and its preparation and application.
Background
Sensitive skin refers to a high-response state of skin under physiological or pathological conditions, which is characterized in that the skin is easy to have subjective symptoms such as burning, stabbing pain and erythema, and objective signs such as erythema, scales and telangiectasia are accompanied or not accompanied, and at present, a plurality of factors causing skin sensitivity can cause the skin to have sensitive reaction, such as oxidative stress reaction caused by ultraviolet irradiation, excessive skin lipid loss, skin barrier function damage, air pollution and the like caused by improper use of cleaning products. More and more people are affected by sensitive skin, researches show that the proportion of the sensitive skin of women is up to 60-70%, and the proportion of the sensitive skin of men is over 50%, so that the soothing products gradually become a great hot spot for research and development in the field of cosmetics.
At present, it is generally believed that the occurrence of sensitive skin is a complex process involving skin barrier-neurovascular-immunoinflammation, and therefore, solving the skin sensitivity problem can be started from the aspect of relieving the skin, for example, the prior art discloses a composition for improving the skin, which achieves the relieving effect by anti-allergy and anti-oxidation, but the composition contains dozens of traditional Chinese medicine extracts such as centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea leaf extract, glycyrrhiza glabra root extract, chamomile flower extract, rosemary leaf extract and the like, and has complex components and complicated preparation process.
Therefore, there is a need to develop a composition with less ingredients and simple process, which is necessary for soothing the skin.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a composition with a relieving effect and preparation and application thereof, and the four traditional Chinese medicine extracts and specific auxiliary materials are compounded through a simple preparation process to realize the anti-allergic and anti-oxidation effects.
The primary object of the present invention is to provide a composition with soothing effect.
The second object of the present invention is to provide a process for the preparation of the above composition.
The third object of the present invention is to provide the use of the above composition for the preparation of a cosmetic product with soothing effect.
It is a fourth object of the present invention to provide a cosmetic with soothing effect.
The above purpose of the invention is realized by the following technical scheme:
the invention provides a composition with a soothing effect, which comprises the following components in percentage by mass: 0.3-1.0% of dipotassium glycyrrhizinate, 0.01-0.5% of peony root extract, 0.05-0.5% of scutellaria root extract, 0.05-0.5% of centella extract, 0.01-0.3% of amino acid, 0.005-0.1% of citric acid, 0.005-0.05% of sodium metabisulfite, 40-60% of polyalcohol and the balance of water.
The invention follows the compatibility principle of 'monarch, minister, assistant and guide' in traditional Chinese medicine, and specific four traditional Chinese medicine extracts, namely dipotassium glycyrrhizinate, radix paeoniae alba extract, radix scutellariae extract and centella asiatica extract, are compounded according to specific dosage, wherein liquorice is a superior herb and is a monarch drug; the scutellaria baicalensis, the peony and the centella asiatica are middle herbs in the grassland and are respectively a minister drug, an assistant drug and a conductant drug according to the effects. The four traditional Chinese medicine extracts synergistically play the roles of resisting allergy and oxidation, so that the effect of relieving the skin is realized; the four traditional Chinese medicine extracts are compounded with specific auxiliary materials such as amino acid, sodium metabisulfite and the like, so that the defects of poor stability, poor water solubility and the like of the traditional Chinese medicine extracts are overcome, the stability of the composition is obviously improved, and the composition is favorably prepared into cosmetics.
According to the invention, a specific product protective agent, namely sodium pyrosulfite, is selected, and is different from other product protective agents (such as disodium ethylene diamine tetraacetate (EDTA-2Na) and tetra (dibutyl hydroxy hydrogen pentaerythritol cinnamate) (TT)), so that the composition can be effectively prevented from discoloring, and the stability of the composition is ensured; in addition, the citric acid in the composition can adjust the pH value of the system, and active ingredients in the composition are prevented from being degraded under the condition of peracid or over-alkali, so that the stability of the composition is ensured.
Preferably, the composition comprises 0.6-0.9% of dipotassium glycyrrhizinate, 0.05-0.2% of peony root extract, 0.1-0.3% of scutellaria root extract, 0.1-0.3% of centella asiatica extract, 0.03-0.1% of amino acid, 0.01-0.03% of citric acid, 0.01-0.04% of sodium metabisulfite, 40-60% of polyhydric alcohol and the balance of water.
Most preferably, dipotassium glycyrrhizinate 0.8%, paeonia radix extract 0.1%, scutellaria radix extract 0.15%, centella asiatica extract 0.2%, amino acids 0.06%, citric acid 0.015%, sodium metabisulfite 0.02%, polyhydric alcohol 50%, and the balance water. See example 1.
Preferably, the paeoniflorin extract contains 40-80 wt% of paeoniflorin. If the radix paeoniae extract with too low paeoniflorin content is adopted, the solubility is poor, and the solution is crystallized; when the extract of radix Paeoniae with high penoniflorin content is used, the solution is easily discolored and unstable, although the solubility is good.
Preferably, the amino acid comprises one or more of arginine, histidine and lysine. Most preferably, the amino acid is arginine, see example 1. The amino acids have repairing effect on macrophage, fibroblast and keratinocyte, and can exert skin soothing effect in cooperation with dipotassium glycyrrhizinate, Scutellariae radix extract, herba Centellae extract and radix Paeoniae extract, and improve solubility of Chinese medicinal extract in system.
Preferably, the polyhydric alcohol comprises one or more of glycerol, butanediol and propylene glycol. Most preferably, the polyol is butanediol, see example 1. The butanediol can not only enhance the moisturizing performance, but also improve the solubility of the composition.
In addition, the invention also provides a preparation method of the composition, which comprises the following steps: adding the radix Scutellariae extract, amino acids and citric acid into water, mixing, adding radix Paeoniae extract, dipotassium glycyrrhizinate, herba Centellae extract, sodium pyrosulfite and polyalcohol, and mixing.
The invention can effectively dissolve the insoluble scutellaria root extract (the solubility of baicalin in water at 25 ℃ is only 0.0037%) by specially controlling the types and the adding sequence of the raw materials, and if the amino acid is added at last, the scutellaria root extract still can be partially or completely not dissolved.
According to the invention, specific four traditional Chinese medicine extracts, namely dipotassium glycyrrhizinate, a peony root extract, a scutellaria root extract and a centella extract, are compounded according to specific dosage, and the antiallergic and antioxidant effects are cooperatively exerted, so that the effect of relieving the skin is realized; the four traditional Chinese medicine extracts are compounded with specific auxiliary materials such as amino acid, sodium metabisulfite and the like, so that the defects of poor stability, poor water solubility and the like of the traditional Chinese medicine extracts are overcome, the stability of the composition is obviously improved, and the composition is favorably prepared into cosmetics, therefore, the application of the composition in preparing the cosmetics with the relieving effect and the cosmetics with the relieving effect containing the composition are both within the protection range of the invention.
Preferably, the concentration of the composition in the cosmetic is 1 to 8 wt%.
Preferably, the cosmetic comprises one or more of spray, essence and cream.
The invention has the following beneficial effects:
according to the invention, specific four traditional Chinese medicine extracts, namely dipotassium glycyrrhizinate, a peony root extract, a scutellaria root extract and a centella extract, are compounded according to specific dosage, and the antiallergic and antioxidant effects are cooperatively exerted, so that the effect of relieving the skin is realized.
The four traditional Chinese medicine extracts are compounded with specific auxiliary materials such as amino acid, sodium metabisulfite and the like, and the defects of poor stability, poor water solubility and the like of the traditional Chinese medicine extracts are overcome by controlling the adding sequence of various raw materials, so that the stability of the composition is obviously improved, the composition can be compatible with various cosmetics in different formulations, and unstable conditions such as color change, precipitation and the like cannot occur.
The composition disclosed by the invention is composed of various natural plant components, is high in safety, can be used for a long time, is suitable for a wide range of people, and is particularly suitable for people with sensitive muscles.
Drawings
FIG. 1 is a photograph of the compositions of examples 1 to 9 at room temperature.
FIG. 2 is a photograph of the compositions of comparative examples 1 to 7 at room temperature.
FIG. 3 is a photograph of comparative examples 8-12 at room temperature.
FIG. 4 is a photograph of comparative examples 13 to 17 at room temperature.
FIG. 5 is a photograph of the composition of example 1 under four different conditions.
FIG. 6 is a photograph of a comparative example 7 composition under four different conditions.
FIG. 7 is a photograph of a comparative example 8 composition under four different conditions.
Fig. 8 is a response probability confidence interval table of example 1.
FIG. 9 is the results of arm skin soothing 15min after application of the sample.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
Examples 1-9 and comparative examples 1-14 preparation of a soothing composition
Firstly, raw materials
Dipotassium glycyrrhizinate with purity not less than 98%, and UV is commercially available;
radix Paeoniae extract with paeoniflorin content of 40-80%, HPLC, and is commercially available;
the baicalin content of the scutellaria root extract is more than or equal to 85 percent, and the extract is sold in the market by HPLC;
centella asiatica extract with centella asiatica total glycoside content not less than 70%, HPLC, and is commercially available.
Second, Experimental methods
According to the dosage of each raw material in tables 1 to 3, 100g of the composition with soothing effect is prepared by the following steps:
adding the radix Scutellariae extract, amino acids and citric acid into water, mixing, adding radix Paeoniae extract, dipotassium glycyrrhizinate, herba Centellae extract, sodium pyrosulfite and polyalcohol, and mixing.
Table 1 examples 1 to 9 amount of each raw material (unit:%) in the composition having soothing effect
TABLE 2 COMPARATIVE EXAMPLES 1 TO 8 COMPOSITION HAVING RELEASE EFFECT IN WHICH THE AMUSES OF THE MATERIAL IN THE COMPOSITIONS (UNIT:%)
TABLE 3 comparative examples 9 to 14 the amount of each raw material used in the composition having soothing effect (unit:%)
Comparative example 15
The same as example 1, except that the paeoniflorin extract contains 10 wt% of paeoniflorin.
Comparative example 16
The same as example 1, except that the paeoniflorin extract contains 98 wt% of paeoniflorin.
Comparative example 17
With the same raw materials and amounts as in example 1, 100g of a soothing composition was prepared according to the following steps:
adding the scutellaria root extract, the paeonia lactiflora root extract, the dipotassium glycyrrhizinate, the centella asiatica extract, the sodium metabisulfite, the citric acid and the butanediol into water in the formula ratio in sequence, mixing uniformly, adding the arginine, and mixing uniformly to obtain the composition.
Examples of the experiments
First, Experimental methods-IC 50 value of composition for hyaluronidase inhibition
1. Principle of experiment
The anti-allergy and relieving effects of the composition are determined by a hyaluronidase in vitro inhibition method. Hyaluronidase is a participant in allergic reactions, decomposes hyaluronic acid in vivo to become an acidic stimulus with low molecular weight, causes histamine release, induces the body to produce sensitive symptoms, and a hyaluronidase inhibition test is a typical anti-allergic activity evaluation in vitro method, evaluates the anti-allergic activity of a composition by taking the hyaluronidase inhibition rate as an index, and the higher the inhibition rate is, the stronger the anti-allergic activity of the composition is, i.e., the lower the IC50 value of the composition on the hyaluronidase inhibition rate is, the stronger the anti-allergic activity of the composition is.
2. Preparing solution
(1)0.1mol/L acetic acid solution (pH 3.6): measuring 1.5mL of glacial acetic acid, diluting the glacial acetic acid to 250mL with ultrapure water, and adjusting the pH value to 3.6 with NaOH;
(2) hyaluronidase solution (7900U/mL): weighing 0.1300g of hyaluronidase, placing the hyaluronidase in a beaker, and adding 5mL of acetic acid buffer solution for dissolution;
(3) sodium hyaluronate solution (1.2 mg/mL): weighing 0.0240g of sodium hyaluronate, placing in a beaker, and adding 20mL of acetic acid buffer solution for dissolving;
(4) calcium chloride solution (12.5 mmol/L): 0.13875g of calcium chloride is weighed, dissolved by ultrapure water and added to 100mL of constant volume;
(5) sodium hydroxide solution (0.4 mol/L): weighing 1.6g of calcium chloride, dissolving with ultrapure water, and metering to 100 mL;
(6) sodium borate solution (0.2 mol/L): 4.0244g of sodium borate is weighed, dissolved by ultrapure water and added to a constant volume of 100 mL;
(7) PDMAB solution: weighing 4.00g of p-dimethylaminobenzaldehyde, adding 50ml of 10mol/L hydrochloric acid solution, and then adding 350ml of glacial acetic acid;
(8) hydrochloric acid solution (10 mol/L): 20.8mL of concentrated hydrochloric acid is weighed out, water is injected until the concentration is 10mol/L, and the mixture is shaken up.
3. IC50 value for determining hyaluronidase inhibition by compositions
The compositions of examples 1 to 9 and comparative examples 1 to 17 were each used to determine the hyaluronidase activity inhibition ratio of the compositions as follows:
s1, taking 50 mu L of 7900U/mL hyaluronidase solution and 50 mu L of composition, and carrying out heat preservation culture at 37 ℃ for 20 min;
s2, adding 50 mu L of 12.5mmol/L calcium chloride solution, and carrying out heat preservation culture at 37 ℃ for 20 min;
s3, adding 250 mu L of 1.2mg/mL sodium hyaluronate solution, and carrying out heat preservation culture at 37 ℃ for 40 min;
s4, adding 50 mu L of 0.4mol/L sodium hydroxide solution and 100 mu L of 0.2mol/L sodium borate solution, heating in a boiling water bath at 100 ℃ for 3min, and immediately cooling to 25 ℃ with ice water;
s5, adding 1.5mL of PDMAB solution, carrying out water bath at 37 ℃ for 20min, taking out, and cooling to 25 ℃ for later use;
s6, scanning a sample by adopting an enzyme labeling instrument at a wavelength of 450-700 nm to determine the maximum absorption wavelength, testing an OD (optical density) value at 585nm, measuring an absorbance value at the maximum absorption wavelength, calculating the hyaluronidase inhibition rate according to a formula (the hyaluronidase inhibition rate/% ([ A-B ]/[ A ] × 100%), wherein A is the absorbance value of a blank group, acetic acid buffer solution is used for replacing sample solution, and B is the absorbance value of the sample group), and carrying out Probit regression analysis by SPSS software to obtain the concentration of the composition when the hyaluronidase inhibition rate is 50%, namely an IC50 value.
Second, Experimental methods-stability of compositions
The purpose of the stability test is to examine the time-dependent behavior of the composition under the influence of temperature and light. In the production, storage and use processes of the composition, the stability of the functional components is influenced by the pH value and temperature of the system, and discoloration, precipitation and the like can occur, so that the effect is reduced, therefore, a stability test provides a scientific basis for the production, packaging, storage and transportation conditions of raw materials, the stability of the composition is judged from the aspects of appearance, color change and crystallization precipitation of the composition by respectively placing examples 1-9 and comparative examples 1-17 at 5 ℃, room temperature (25 ℃) and 50 ℃ under illumination for stability inspection.
Third, experimental results
The IC50 values for hyaluronidase inhibition and product stability results for the compositions of examples 1-9 and comparative examples 1-17 are shown in Table 4.
TABLE 4
As is clear from Table 1, the compositions of examples 1 to 9 had an IC50 value of 3.48 to 5.75% for the hyaluronidase inhibition rate, while the compositions of comparative examples 1 to 9 and 14 had an IC50 value of 10% or more for the hyaluronidase inhibition rate.
In addition, photographs of the compositions of examples 1 to 9 and comparative examples 1 to 17 at room temperature are shown in FIGS. 1 to 4, and FIG. 1 shows that the compositions of examples 1 to 9 do not change color and precipitate at room temperature; FIG. 2 shows that comparative examples 2, 5 and 6 all crystallized at room temperature, and comparative example 7 changed from yellow to red in color; FIG. 3 shows that comparative example 8 darkens at room temperature; FIG. 4 shows that comparative examples 13 and 16 both turned yellow to red in color, and comparative examples 15 and 17 had different degrees of crystallization. The photographs of example 1 at 5 ℃, room temperature (25 ℃), 50 ℃, and light are shown in FIG. 5, which shows that the composition of example 1 does not change color or precipitate under the four conditions, and has extremely high stability; comparative example 7 photographs at 5 deg.C, room temperature (25 deg.C), 50 deg.C, and light are shown in FIG. 6, and it can be seen that the composition of comparative example 7 has color change of different degrees and very poor stability under any conditions; comparative example 8 photographs at 5 deg.C, room temperature (25 deg.C), 50 deg.C and light irradiation are shown in FIG. 7, and it can be seen that the composition of comparative example 8 has different degrees of color change at room temperature (25 deg.C) and 50 deg.C, and is inferior in stability. The Probit modeling was performed using SPSS to obtain the response probability confidence interval table of example 1, and as shown in fig. 8, it was found that the half inhibition concentration (IC50 value) was 3.48% when the response probability was 0.5.
It can be seen from Table 4 and FIGS. 1 to 8 that:
(1) the comparative examples 1-4 are only added with one traditional Chinese medicine extract (the total mass of the traditional Chinese medicine extract is unchanged), the IC50 value (10-50%) of the hyaluronidase inhibition rate of the obtained composition is obviously higher than that of the example 1 (3.48%), and the composition only added with one traditional Chinese medicine extract can not effectively inhibit the activity of hyaluronidase;
(2) comparative example 5 lacks arginine and comparative example 6 lacks butanediol, and the resulting compositions all crystallized at room temperature, indicating that arginine and butanediol are not essential for the compositions of the present invention, and that the absence of either component results in a decrease in the solubility of the composition;
(3) comparative example 7 lacks citric acid and comparative example 8 lacks sodium metabisulfite, and the color of the resulting composition changes, indicating that citric acid and sodium metabisulfite are not essential for the composition of the present invention, and the absence of either component results in poor stability of the composition;
(4) comparative examples 9 to 12 lack one of the four traditional Chinese medicine extracts (the total mass of the traditional Chinese medicine extracts is unchanged), the IC50 value (8.20 to 30%) of the hyaluronidase inhibition rate of the obtained composition is significantly higher than that of example 1 (3.48%), which shows that dipotassium glycyrrhizinate, radix paeoniae alba extract, radix scutellariae extract and centella asiatica extract are all indispensable to the composition of the invention, and the lack of any one of the components can cause the significant deterioration of the antiallergic activity of the composition;
(5) comparative examples 13 and 14 respectively adopt other product protective agents EDTA-2Na, TT, the color of the obtained composition has changed at room temperature, which shows that only the specific product protective agent sodium pyrosulfite can effectively prevent the composition from changing color and ensure the stability of the composition;
(6) comparative example 15 using an extract of radix Paeoniae with too low a content of paeoniflorin, the resulting composition crystallized at room temperature; comparative example 16 using the extract of radix Paeoniae with too high a content of paeoniflorin, the color of the obtained composition changed at room temperature; the stability of the composition can be effectively ensured only by adopting the paeony root extract with specific paeoniflorin content;
(7) comparative example 17, the amino acid was added to the end, and the obtained composition crystallized at room temperature, indicating that the stability of the composition can be effectively ensured only by strictly controlling the addition sequence of the raw materials.
Application example
First, spray preparation
(1) Application example 1-1
Taking the composition of example 1, 100g of a soothing spray was prepared according to the following procedure: heating phase A raw materials (EDTA-2Na 0.05g, butanediol 5g, pentanediol 1g, hexanediol 0.5g, p-hydroxyacetophenone 0.2g, allantoin 0.1g, deionized water to make up 100g) to 80 deg.C, mixing, and keeping the temperature for 30 min; and (3) when the temperature is reduced to 45 ℃, adding the phase B raw materials (5 g of the composition in example 1, 2g of panthenol and 0.05g of essence), and uniformly stirring and dispersing to obtain the spray with the relieving effect.
(2) Application examples 1 to 2
The spray of application example 1-1 was repeated except that the composition of example 1 was used in an amount of 1 part by mass.
(3) Application examples 1 to 3
The spray of application example 1-1 was repeated except that the composition of example 1 was used in an amount of 8 parts by mass.
(4) Application comparative examples 1 to 17
The spray of application example 1-1 was repeated except that the compositions of comparative examples 1 to 17 were used instead of the composition of example 1.
Second, Experimental method-inhibition of sprayed hyaluronidase
The hyaluronidase inhibition rates of the compositions of example 1 were determined by the methods of application example 1-1, application example 1-2, application example 1-3 and application comparative examples 1-17.
Third, Experimental method-DPPH radical scavenging ratio of spray
1. Principle of experiment
DPPH is also called 1, 1-diphenyl-2-trinitrophenylhydrazine, is a very stable free radical with a nitrogen center, and the ethanol solution of DPPH is purple and has strong absorption at the wavelength of 517 nm. When the free radical scavenger exists, the light absorption of the DPPH ethanol solution is weakened due to the pairing of electrons of the free radical scavenger, and the fading degree of the DPPH ethanol solution is in a linear relation with the number of the electrons accepted by the DPPH ethanol solution, so that the capability of a test sample for scavenging free radicals, namely the antioxidant activity, can be evaluated.
2. Preparing solution
DPPH (1, 1-diphenyl-2-trinitrophenylhydrazine): not less than 98.5% (HPLC), Ron; anhydrous ethanol: and AR.
(1)0.2mmol/L of ethanol DPPH solution (as free radical): 78.86mg of DPPH was dissolved in 1000mL of absolute ethanol;
(2) sample solution (as radical scavenger): spray dope of application example 1-1, application example 1-2, application example 1-3 and application comparative examples 1 to 17.
3. Determination of DPPH radical scavenging Rate of spray
(1) Sequentially adding 75 μ L sample solution and 75 μ L0.2 mmol/LDPPH alcohol solution into sample well of enzyme label plate at 25 deg.C, mixing, standing for 30min, measuring light absorption value at wavelength of 517nm with enzyme label instrument, and recording data as A1；
(2) Sequentially adding 75 μ L water and 75 μ L0.2 mmol/L DPPH ethanol solution into sample well of enzyme label plate, mixing, standing for 30min, measuring light absorption value at wavelength of 517nm with enzyme label reader as sample solvent blank control group, and recording data as A2；
(3) Sequentially adding 75 μ L sample solution and 75 μ L water into sample well of enzyme labeling plate, mixing, standing for 30min, measuring light absorption value at wavelength of 517nm with enzyme labeling instrument as reagent blank control group, and recording data as A0。
(4) According to the formula
The DPPH radical clearance of the spray was calculated.
Fourth, experiment method-spray yam stimulation-relieving experiment
1. Principle of experiment
The skin can generate uncomfortable feelings such as stabbing pain, red swelling and the like by contacting a small amount of Chinese yam, the stabbing pain feeling and the red rash are graded through a test subject (4-point grading standard: 0 is no feeling, 1 is mild feeling, 2 is moderate feeling, 3 is severe feeling, and 4 is very severe feeling), when the grading value is larger than or equal to 2, the yam is used as a stimulation end point, then a test sample is smeared, and the effect of the test sample on immediately relieving stimulation can be evaluated through the fading degree of the uncomfortable feelings.
2. Sample (I)
Test samples: the spray prepared in example 1-1 was used;
control sample: the spray prepared in application example 1-1 was used, but without addition of the composition of example 1;
blank sample: deionized water.
3. Experimental methods
In an environment with the temperature of 22-24 ℃ and the relative humidity of 40-60%, the skin of the inner area of one arm of 6 18-40-year-old female subjects is randomly selected, 3 circular areas with the diameter of 2cm are selected, and the skin is respectively a test group, a blank group and a control group from the elbow to the palm. During the test, the yam stick is smeared on a tested area for 5 times, when the score obtained by the score of a subject is more than or equal to 2 points (the average value of the scores of 6 subjects is taken), a tester smears a test sample on the test area of a test group, smears a control sample on the test area of a control group, smears a blank sample on the test area of a blank group, and the sample smearing amount of three groups is 12 mu L and is recorded as 0min at the moment. The subjects scored the tingling and rash 5min, 15min, and 30min after sample application.
Fifth, experimental results
1. Hyaluronidase inhibition and DPPH free radical scavenging results
The results of the hyaluronidase inhibition ratios and DPPH radical clearance ratios of the sprays of application examples 1-1, application examples 1-2, application examples 1-3, and application comparative examples 1-17 are shown in Table 5.
TABLE 5
| Hyaluronidase inhibition/%) | DPPH radical clearance% | |
| Application example 1-1 | 80 | 97 |
| Application examples 1 to 2 | 72 | 90 |
| Application examples 1 to 3 | 80 | 97 |
| Application comparative example 1 | 20 | 30 |
| Comparative application example 2 | 40 | 40 |
| Comparative application example 3 | 42 | 50 |
| Application comparative example 4 | 40 | 40 |
| Comparative application example 5 | 30 | 35 |
| Comparative application example 6 | 30 | 40 |
| Application comparative example 7 | 48 | 58 |
| Comparative application example 8 | 32 | 40 |
| |
32 | 45 |
| Comparative application example 10 | 48 | 57 |
| Comparative application example 11 | 46 | 59 |
| Comparative application example 12 | 40 | 52 |
| Comparative application example 13 | 46 | 65 |
| Comparative application example 14 | 47 | 64 |
| Comparative application example 15 | 42 | 58 |
| Comparative application example 16 | 44 | 58 |
| Comparative application example 17 | 44 | 58 |
As can be seen from table 5, both the hyaluronidase inhibition rate and DPPH radical clearance rate of the spray of application examples 1-1, application examples 1-2, and application examples 1-3 are significantly better than those of application comparative examples 1-17, and it can be seen that when the composition of example 1 is prepared into a spray, the antiallergic and antioxidant effects are significantly better than those of comparative examples 1-17, which indicates that the specific four herbal extracts, i.e., dipotassium glycyrrhizinate, radix paeoniae alba extract, radix scutellariae extract, and centella asiatica extract, are compounded in specific amounts, so that the antiallergic and antioxidant effects can be synergistically exerted, and thus the skin soothing effect can be realized; the four traditional Chinese medicine extracts are compounded with specific auxiliary materials such as amino acid, sodium metabisulfite and the like, and the defects of poor stability, poor water solubility and the like of the traditional Chinese medicine extracts are overcome by controlling the adding sequence of various raw materials, so that the stability of the composition is obviously improved, the composition can be compatible with cosmetics of various different formulations, and unstable conditions such as color change, precipitation and the like cannot occur.
2. Results of Yam stimulation-relief experiment
The results of the yam irritation-soothing test using the spray of example 1-1 are shown in table 6, wherein the soothing of the arm skin 15min after application of the sample is shown in fig. 9, zone 1 represents the test group, zone 2 represents the blank group, and zone 3 represents the control group.
TABLE 6 discomfort score results
As can be seen from table 6 and fig. 9, the test group (application example 1-1) relieved discomfort such as stinging and rash caused by yam stimulation more quickly than the other groups (control group and blank group), and complete skin relief was achieved within 30 min.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. The composition with the relieving effect is characterized by comprising the following components in percentage by mass: 0.3-1.0% of dipotassium glycyrrhizinate, 0.01-0.5% of peony root extract, 0.05-0.5% of scutellaria root extract, 0.05-0.5% of centella extract, 0.01-0.3% of amino acid, 0.005-0.1% of citric acid, 0.005-0.05% of sodium metabisulfite, 40-60% of polyalcohol and the balance of water.
2. The composition according to claim 1, wherein the composition comprises 0.6-0.9% dipotassium glycyrrhizinate, 0.05-0.2% radix Paeoniae extract, 0.1-0.3% radix Scutellariae extract, 0.1-0.3% centella asiatica extract, 0.03-0.1% amino acid, 0.01-0.03% citric acid, 0.01-0.04% sodium metabisulfite, 40-60% polyhydric alcohol, and the balance of water.
3. The composition of claim 1, wherein the radix Paeoniae extract contains paeoniflorin in an amount of 40-80 wt%.
4. The composition of claim 1, wherein the amino acid comprises one or more of arginine, histidine, and lysine.
5. The composition of claim 1, wherein the polyol comprises one or more of glycerin, butylene glycol, and propylene glycol.
6. The method for preparing the composition according to any one of claims 1 to 5, wherein the composition is prepared by sequentially adding the scutellaria root extract, the amino acid and the citric acid into water, mixing, adding the paeonia root extract, the dipotassium glycyrrhizinate, the centella asiatica extract, the sodium metabisulfite and the polyalcohol, and mixing.
7. Use of a composition according to any one of claims 1 to 5 for the preparation of a cosmetic product with soothing effect.
8. A soothing cosmetic comprising the composition of any of claims 1 to 5.
9. Use according to claim 7 or cosmetic product according to claim 8, wherein the composition is present in the cosmetic product in a concentration of 1 to 8% by weight.
10. The use according to claim 7 or the cosmetic according to claim 8, wherein the cosmetic comprises one or more of a spray, a serum, a cream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210253643.1A CN114632040B (en) | 2022-03-15 | 2022-03-15 | Composition with relieving effect and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210253643.1A CN114632040B (en) | 2022-03-15 | 2022-03-15 | Composition with relieving effect and preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114632040A true CN114632040A (en) | 2022-06-17 |
| CN114632040B CN114632040B (en) | 2022-09-13 |
Family
ID=81948325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210253643.1A Active CN114632040B (en) | 2022-03-15 | 2022-03-15 | Composition with relieving effect and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114632040B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115813831A (en) * | 2023-01-10 | 2023-03-21 | 广东雅丽洁精细化工有限公司 | Composition with anti-allergy and relieving effects and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100273729A1 (en) * | 2006-12-15 | 2010-10-28 | Biospectrum, Inc. | Compositions Comprising Compounds Of Natural Origin For Damaged Skin |
| CN108096095A (en) * | 2017-12-27 | 2018-06-01 | 珠海伊斯佳科技股份有限公司 | A kind of composite whitening and composition and its application for soothing the skin stimulatory function |
| CN108542852A (en) * | 2018-07-05 | 2018-09-18 | 深圳市茗润生物科技有限公司 | A kind of skin is releived composition and preparation method thereof |
-
2022
- 2022-03-15 CN CN202210253643.1A patent/CN114632040B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100273729A1 (en) * | 2006-12-15 | 2010-10-28 | Biospectrum, Inc. | Compositions Comprising Compounds Of Natural Origin For Damaged Skin |
| CN108096095A (en) * | 2017-12-27 | 2018-06-01 | 珠海伊斯佳科技股份有限公司 | A kind of composite whitening and composition and its application for soothing the skin stimulatory function |
| CN108542852A (en) * | 2018-07-05 | 2018-09-18 | 深圳市茗润生物科技有限公司 | A kind of skin is releived composition and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115813831A (en) * | 2023-01-10 | 2023-03-21 | 广东雅丽洁精细化工有限公司 | Composition with anti-allergy and relieving effects and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114632040B (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111388376B (en) | Jasmine herbal anti-allergy soothing mask and preparation method thereof | |
| CN113499290B (en) | Composition with relieving and repairing effects and preparation method and application thereof | |
| CN116549378A (en) | Rectal mucosa administration preparation of pulsatilla chinensis saponin B4 and preparation method thereof | |
| CN114632040B (en) | Composition with relieving effect and preparation and application thereof | |
| Cong et al. | Attenuation of renal ischemia/reperfusion injury by a polysaccharide from the roots of Dipsacus asperoides | |
| CN110623895A (en) | Anti-allergy relieving composition and preparation method and application thereof | |
| CN110075059B (en) | Composition capable of resisting allergy, relieving itching and repairing | |
| CN111514072A (en) | Millettia speciosa-noni composite enzyme, preparation method thereof and application of millettia speciosa-noni composite enzyme in preparation of facial mask | |
| CN103751316B (en) | A kind of there is antifungal activity waistcoat seed extract and all kinds of preparation and application | |
| CN106236676B (en) | Plant composition with anti-aging effect and application thereof | |
| EP3738581A1 (en) | Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor | |
| CN104666873B (en) | External medicine composition, preparation with the antipruritic anti-inflammatory efficacies of Shu Min and preparation method thereof | |
| CN107751527A (en) | The preparation method and Chinese herbal medicine candy of a kind of pharynx-clearing throat-benefiting Chinese herbal medicine candy | |
| CN111419744A (en) | Anti-saccharification skin cream and preparation method thereof | |
| CN113398182A (en) | Traditional Chinese medicine composition for inhibiting activity of hyaluronidase and hyaluronidase inhibitor | |
| CN113057981A (en) | Compound temperature-sensitive gel and preparation method and application thereof | |
| CN113499271A (en) | Anti-allergy compound and preparation method and application thereof | |
| CN102631609B (en) | Externally used traditional Chinese medicine composition with emergency skin repair effect, preparation and preparation method thereof | |
| CN116585242B (en) | Moisturizing and soothing composition and preparation method thereof | |
| KR20210035195A (en) | Composition comprising glycyrin and its cosmetic and pharmaceutical use | |
| CN113274304B (en) | High-purity licorice flavone micro-emulsion composition and preparation method thereof | |
| CN115337265B (en) | Development of veterinary medicine-loquat leaf extract injection | |
| CN114404329B (en) | Hippophae rhamnoides anti-aging composition and preparation method thereof | |
| CN112569309A (en) | Throat-clearing and cough-relieving powder as well as preparation process and use method thereof | |
| CN113893287B (en) | External traditional Chinese medicine preparation for treating eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |